COVID-19 Is Bigger Cause Of Neurological Problems Than Vaccinations, Says UK Study

A study released Monday revealed that COVID-19 vaccines do not carry a major risk of developing neurological problems, and exposure to the virus itself carries a greater risk of contracting any side effects.

The study was published in Nature Magazine and was a joint effort between the University of Edinburgh and Oxford University.

Using medical records of 32 million adults, researchers compared levels of neurological conditions seen within a month of having a first vaccine jab, to those seen within a month of a positive COVID-19 test. Specifically, they looked for a rare condition called Guillain-Barre Syndrome (GBS) known to be associated with certain infectious diseases and linked to some other vaccines.

GBS causes inflammation of the nerves and can lead to numbness, weakness and pain, usually in the feet, hands and limbs, but can spread further. It is usually considered treatable but there are cases where it can be serious enough to be life-threatening.

The results found 38 extra cases of GBS for every 10 million adults who received the Oxford-AstraZeneca vaccine versus 60 extra cases of brain bleeding for every 10 million adults having the Pfizer vaccine. In contrast, 145 extra GBS cases per 10 million who tested positive for COVID-19. In addition, it found 123 extra brain inflammation disorder cases and 163 extra cases of nerve or muscle disorders in the same sample.

This study confirms that the chances of suffering serious side effects from receiving COVID-19 vaccines as opposed to the effects experienced from catching the virus. It also reinforces the efficacy of COVID-19 vaccines when compared to the disproven and often dangerous alternative remedies offered by opponents of the vaccines.

The U.K. has grown concerned with a new surge in COVID-19 cases despite boasting a strong vaccination rate. British health officials encourage citizens to receive booster shots if possible and they are warning that lockdowns could be back on the table if infections go up too much in the future.